SVB Leerink reiterated coverage on MannKind with a new price target
$MNKD
Biotechnology: Pharmaceutical Preparations
Health Care
SVB Leerink reiterated coverage of MannKind with a rating of Outperform and set a new price target of $5.00 from $3.00 previously